LLY

917.46

+0.11%↑

JNJ

237.66

+0.19%↑

ABBV

206.13

-1.03%↓

NVS

148.1

-1.11%↓

AZN

188.8

+0.2%↑

LLY

917.46

+0.11%↑

JNJ

237.66

+0.19%↑

ABBV

206.13

-1.03%↓

NVS

148.1

-1.11%↓

AZN

188.8

+0.2%↑

LLY

917.46

+0.11%↑

JNJ

237.66

+0.19%↑

ABBV

206.13

-1.03%↓

NVS

148.1

-1.11%↓

AZN

188.8

+0.2%↑

LLY

917.46

+0.11%↑

JNJ

237.66

+0.19%↑

ABBV

206.13

-1.03%↓

NVS

148.1

-1.11%↓

AZN

188.8

+0.2%↑

LLY

917.46

+0.11%↑

JNJ

237.66

+0.19%↑

ABBV

206.13

-1.03%↓

NVS

148.1

-1.11%↓

AZN

188.8

+0.2%↑

Search

Heron Therapeutics Inc

Avatud

SektorTervishoid

0.81 -1.22

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

0.78

Max

0.83

Põhinäitajad

By Trading Economics

Sissetulek

15M

-3M

Müük

2.4M

41M

Aktsiakasum

-0.02

Kasumimarginaal

-7.278

Töötajad

128

EBITDA

13M

-792K

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+417.24% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

5. mai 2026

Turustatistika

By TradingEconomics

Turukapital

-49M

169M

Eelmine avamishind

2.03

Eelmine sulgemishind

0.81

Uudiste sentiment

By Acuity

50%

50%

171 / 351 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

Heron Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

18. märts 2026, 22:51 UTC

Tulu

AIA Group Value of New Business Rose in 2025, Plans $1.7 Billion New Share Buyback

18. märts 2026, 21:40 UTC

Omandamised, ülevõtmised, äriostud

Constellation Energy to Sell Portfolio of Assets for $5 Billion to Satisfy Regulators

18. märts 2026, 20:31 UTC

Tulu

Micron 2Q Sales Nearly Triple Amid Tight Memory Supply

18. märts 2026, 23:49 UTC

Market Talk
Uudisväärsed sündmused

Nikkei May Fall on Renewed Concerns About Higher Energy Prices -- Market Talk

18. märts 2026, 23:31 UTC

Market Talk

Gold Rises on Likely Technical Recovery -- Market Talk

18. märts 2026, 22:49 UTC

Market Talk

New Zealand's Economic Recovery Has Yet to Find Footing -- Market Talk

18. märts 2026, 22:41 UTC

Market Talk

Woodside Energy Opts for 'Safe, Experienced' Choice as CEO -- Market Talk

18. märts 2026, 22:36 UTC

Tulu

AIA Group Value of New Business Rose in 2025, Plans $1.7B New Share Buyback

18. märts 2026, 22:24 UTC

Tulu

AIA Group Announces New Share Buyback of $1.7B >1299.HK

18. märts 2026, 22:23 UTC

Tulu

AIA Group 2025 Value of New Business Margin Was 58.5%, Up 3.6 Ppt on Year >1299.HK

18. märts 2026, 22:23 UTC

Tulu

AIA Group 2025 Value of New Business $5.52B Vs. $4.71B >1299.HK

18. märts 2026, 21:58 UTC

Tulu

Micron Sales Nearly Triple Amid Tight Memory Supply -- Update

18. märts 2026, 21:55 UTC

Market Talk
Tulu

Global Equities Roundup: Market Talk

18. märts 2026, 21:55 UTC

Market Talk
Tulu

Micron's Phone, PC Business Could Shrink Due to Memory Shortage -- Market Talk

18. märts 2026, 21:40 UTC

Market Talk

Fuel Price Rise Equates to 20 Bps Rate Hike on Australian Households -- Market Talk

18. märts 2026, 21:16 UTC

Market Talk

More Procter & Gamble Alumni Join Strobel at Coty -- Market Talk

18. märts 2026, 21:00 UTC

Uudisväärsed sündmused

Iran War Puts Pressure on Japan's Economy. Takaichi Is In a Bind. -- Barrons.com

18. märts 2026, 20:58 UTC

Tulu

Micron 2Q Gross Margin Nearly Doubled Due to Higher Pricing, CFO Says

18. märts 2026, 20:41 UTC

Tulu

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

18. märts 2026, 20:29 UTC

Tulu

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

18. märts 2026, 20:25 UTC

Tulu

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

18. märts 2026, 20:17 UTC

Tulu

These Stocks Are Today's Movers: Micron, Swarmer, Lumentum, Trade Desk, Macy's, Williams-Sonoma, and More -- Barrons.com

18. märts 2026, 20:14 UTC

Market Talk

Airlines Can't Offset Higher Fuel Prices for Long -- Market Talk

18. märts 2026, 20:09 UTC

Tulu

Micron Reports Extraordinary Earnings. The Stock Is Up. -- Barrons.com

18. märts 2026, 20:07 UTC

Tulu

Micron Technology Raises Qtr Dividend to 15c Vs. 11.5c >MU

18. märts 2026, 20:06 UTC

Tulu

Micron Technology Board Has Approved 30% Increase in Qtrly Div >MU

18. märts 2026, 20:04 UTC

Tulu

Micron Technology 2Q Operating Cash Flow $11.9 B >MU

18. märts 2026, 20:04 UTC

Tulu

Micron Technology Sees 3Q Operating Expenses About $1.6 B >MU

18. märts 2026, 20:04 UTC

Tulu

Micron Technology Sees 3Q Gross Margin About 81% >MU

18. märts 2026, 20:03 UTC

Tulu

Micron Technology Sees 3Q Adj EPS $19.15 +/- 40c >MU

Võrdlus sarnastega

Hinnamuutus

Heron Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

417.24% tõus

12 kuu keskmine prognoos

Keskmine 4.5 USD  417.24%

Kõrge 6 USD

Madal 3 USD

Põhineb 2 Wall Streeti analüütiku instrumendi Heron Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

2

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

2.0001 / 2.42Toetus ja vastupanu

Lühikene perspektiiv

Bearish Evidence

Keskpikk perspektiiv

Bullish Evidence

Pikk perspektiiv

Bullish Evidence

Sentiment

By Acuity

171 / 351 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Heron Therapeutics Inc

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.
help-icon Live chat